Summary
Codeine is an opioid analgesic used to treat moderate to severe pain when the use of an opioid is indicated.
Brand Names
Ascomp, Cheratussin, Cheratussin Dac, Codar Ar, Codar D, Codar Gf, Codeine Contin, Covan, Damylin With Codeine, Fioricet With Codeine, Histex Ac, Linctus Codeine Blanc, M-clear Wc, M-end PE, Mar-cof BP, Mar-cof Cg, Mersyndol, Ninjacof Xg, Pseudodine C, Robaxacet-8, Robaxisal, Triacin-C, Trianal C, Triatec, Triatec-30, Triatec-8, Tusnel C, Tuxarin, Tuzistra, Tylenol With Codeine
Generic NameCodeine
DrugBank Accession NumberDB00318
Background
The relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US in 1950 and is a drug used to decrease pain by increasing the threshold for pain without impairing consciousness or altering other sensory functions. Opiates such as codeine are derived from the poppy plant, Papaver somniferum (Papaveraceae).4
Codeine is utilized as a central analgesic, sedative, hypnotic, antinociceptive, and antiperistaltic agent, and is also recommended in certain diseases with incessant coughing.Label,4
ModalitySmall Molecule
GroupsApproved, Illicit, Investigational
WeightAverage: 299.3642
Monoisotopic: 299.152143543
Chemical FormulaC18H21NO3
Synonyms
- Codein
- Codeína
- Codéine
- Codeine polistirex
- Codeinum
- Methylmorphine

The AI Assistant built for biopharma intelligence.
Access detailed, actionable insights to your most complex research questions. Leverage validated reasoning and citable data to power your critical research decisions.
Indication
Codeine sulfate is a form of this drug that is commonly used. It is available in tablet form Label and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate Label.
The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above 14, 15.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Pharmacodynamics
General effects
Codeine is a weak narcotic pain reliever and cough suppressant that is similar to morphine and hydrocodone. A small amount of ingested codeine is converted to morphine in the body. Codeine increases tolerance to pain, reducing existing discomfort. In addition to decreasing pain, codeine also causes sedation, drowsiness, and respiratory depression 4.
Antitussive activity
This drug has shown antitussive activity in clinical trials 6 and has been effective in cough secondary to tuberculosis and insomnia due to coughing 4. Codeine suppresses the cough reflex through a direct effect on the cough center in the medulla 18.
Effects on intestinal motility
Codeine may reduce intestinal motility through both a local and possibly central mechanism of action 19. This may possibly lead to constipation 18. The chronic use of opioids, including codeine sulfate, may lead to obstructive bowel disease, particularly in patients with underlying disorders of intestinal motility Label.
Effects on the central nervous system
Codeine phosphate is an opioid analgesic with uses similar to those of morphine, but is much less potent as an analgesic. Its primary site of action is at the mu opioid receptors distributed throughout the central nervous system. The sedative activities of codeine are less potent than those of morphine 18. Codeine may cause respiratory system depression by the activation of μ-opioid receptors at specific sites in the central nervous system 8.
Effects on blood pressure
This drug poses an increased risk of compromised ability to maintain blood pressure due to peripheral vasodilation and other mechanisms Label.
Effects on chronic cancer pain and other types of pain
Codeine is an opioid analgesic with similar indications to those of morphine, however, is much less potent in its pain alleviating properties. Its primary action takes place at the mu opioid receptors, which are distributed throughout the central nervous system. The average duration of action is about 4 hours 18.
Regular dosing of opioid analgesics such as codeine in patients with severe cancer pain has been well documented to improve symptoms 4, 7.
Mechanism of action
Although the exact mechanism of action of codeine is still unknown, it is generally thought to be mediated through the agonism of opioid receptors, particularly the mu-opioid receptors.4 Morphine was previously postulated to contribute to the analgesic effect of codeine due to the O-demethylation of codeine to morphine by CYP2D6. Particularly, CYP2D6 poor metabolizer did not experience the analgesic effect of codeine.2,10 However, this is unlikely to be the main mechanism of action of codeine as only 5% of codeine is metabolized to morphine.2 Other hypotheses also postulate that codeine-6-glucuronide, the main metabolite of codeine, mediates the analgesic effect of codeine as it not only has an affinity to the mu receptors as codeine but also can be metabolized to morphine-6-glucuronide, which was observed to be more potent than morphine.3
Binding to the mu receptors by codeine activates the G-proteins Gαi, causing a decrease in intracellular cAMP and Ca2+ level.11,12 This causes hyperpolarization of nociceptive neurons, thus imparing the transmission of pain signals.11,12
Absorption
Absorption
Codeine is absorbed from the gastrointestinal tract. The maximum plasma concentration occurs 60 minutes after administration Label.
Food Effects
When 60 mg codeine sulfate was given 30 minutes post-ingestion of a high high-calorie meal, there was no significant change in the absorption of codeine Label.
Steady-state concentration
The administration of 15 mg codeine sulfate every 4 hours for 5 days lead to steady-state concentrations of codeine, morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) within 48 hours Label.
Volume of distribution
Apparent volume of distribution: about 3-6 L/kg, showing an extensive distribution of the drug into tissues Label.
Protein binding
7-25% bound to plasma proteins Label.
Metabolism
Approximately 70 to 80% of the ingested dose of codeine is metabolized in the liver by conjugation with glucuronic acid to codeine-6 glucuronide (C6G) and by O-demethylation to morphine (about 5-10%) and N-demethylation to norcodeine (about 10%) respectively. UDP-glucuronosyltransferase (UGT) 2B7 and 2B4 are the major metabolic enzymes mediating the glucurodination of codeine to the metabolite, codeine 6 glucuronide.
Cytochrome P450 2D6 is the major enzyme responsible for the transformation of codeine to morphine and P450 3A4 is the main enzyme mediating the conversion of codeine to norcodeine. Morphine and norcodeine are then further metabolized by conjugation with glucuronic acid. The glucuronide metabolites of morphine are morphine-3-glucuronide (M3G) and_ morphine-6-glucuronide _(M6G). Morphine and M6G have been proven to have analgesic activity in humans. The analgesic activity of C6G in humans is not known at this time. Norcodeine and M3G are generally not considered to have analgesic properties Label.
Hover over products below to view reaction partners
Route of elimination
About 90% of the total dose of codeine is excreted by the kidneys. Approximately 10% of the drug excreted by the kidneys is unchanged codeine Label.
The majority of the excretion products can be found in the urine within 6 hours of ingestion, and 40-60 % of the codeine is excreted free or conjugated, approximately 5 to 15 percent as free and conjugated morphine, and approximately 10-20% free and conjugated norcodeine 18.
Half-life
Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours Label.
Clearance
Renal clearance of codeine was 183 +/- 59 ml min-1 in a clinical study 5.
Renal impairment may decrease codeine clearance Label.
Adverse Effects

Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
Toxicity
Oral LD50: 427 mg kg-1 (rat) MSDS.
Overdose/toxicity
Symptoms of opioid toxicity may include confusion, somnolence, shallow breathing, constricted pupils, nausea, vomiting, constipation and a lack of appetite. In severe cases, symptoms of circulatory and respiratory depression may ensue, which may be life-threatening or fatal 13, Label.
Teratogenic effects
This drug is classified as a pregnancy Category C drug. There are no adequate and well-controlled studies completed in pregnant women. Codeine should only be used during pregnancy if the potential benefit outweighs the potential risk of the drug to the fetus Label.
Codeine has shown embryolethal and fetotoxic effects in the hamster, rat as well as mouse models at about 2-4 times the maximum recommended human dose Label. Maternally toxic doses that were about 7 times the maximum recommended human dose of 360 mg/day, were associated with evidence of bone resorption and incomplete bone ossification. Codeine did not demonstrate evidence of embrytoxicity or fetotoxicity in the rabbit model at doses up to 2 times the maximum recommended human dose of 360 mg/day based on a body surface area comparison Label.
Nonteratogenic effects
Neonatal codeine withdrawal has been observed in infants born to addicted and non-addicted mothers who ingested codeine-containing medications in the days before delivery. Common symptoms of narcotic withdrawal include irritability, excessive crying, tremors, hyperreflexia, seizures, fever, vomiting, diarrhea, and poor feeding. These signs may be observed shortly following birth and may require specific treatment Label.
Codeine (30 mg/kg) given subcutaneously to pregnant rats during gestation and for 25 days after delivery increased the rate of neonatal mortality at birth. The dose given was 0.8 times the maximum recommended human dose of 360 mg/day Label.
The use in breastfeeding/nursing
Codeine is secreted into human milk. The maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants Label.
Pharmacogenomic Effects/ADRs

The AI Assistant built for biopharma intelligence.
Access detailed, actionable insights to your most complex research questions. Leverage validated reasoning and citable data to power your critical research decisions.
Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Food Interactions
- Avoid alcohol.
- Take with food. Food reduces irritation.
International/Other BrandsActacode (Sigma) / Bisoltus (Boehringer Ingelheim) / Bromophar (Qualiphar) / Bronchicum (Sanofi-Aventis) / Bronchodine (Pharmacobel) / Codant (Antigen) / Codedrill (Pierre Fabre) / Codein (Cristália) / Codeisan (Belmac) / Coderpina (Frycia Centro América) / Codicalm (Welti) / Codicept / Codinex (Pinewood) / Coducept / Cougel (Hwang’s) / Coutan (Mey See) / Dinco (Center) / Farmacod (Farmacom) / Galcodine (Thornton & Ross) / Pectoral (Siphat) / Tussoret (MaxMedic)
Brand Name Prescription Products
Generic Prescription Products
Over the Counter Products
Unapproved/Other Products
Chemical Taxonomy
Provided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Sub ClassNot Available
Substituents
Alcohol / Alkyl aryl ether / Amine / Anisole / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Coumaran / Ether
show 15 moreMolecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
morphinane alkaloid, organic heteropentacyclic compound (CHEBI:16714) / Isoquinoline alkaloids (C06174)CAS number76-57-3
InChI KeyOROGSEYTTFOCAN-DNJOTXNNSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraen-14-ol
SMILES
[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC
Synthesis Reference
Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, “Process for the preparation of codeine from morphine.” U.S. Patent US4764615, issued May, 1912.
US4764615General References
- Schroeder K, Fahey T: Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001831. [Article]
- Vree TB, van Dongen RT, Koopman-Kimenai PM: Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000 Jul-Aug;54(6):395-8. [Article]
- Srinivasan V, Wielbo D, Tebbett IR: Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain. 1997;1(3):185-90. [Article]
- Bhandari M, Bhandari A, Bhandari A: Recent updates on codeine. Pharm Methods. 2011 Jan;2(1):3-8. doi: 10.4103/2229-4708.81082. [Article]
- Chen ZR, Somogyi AA, Reynolds G, Bochner F: Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol. 1991 Apr;31(4):381-90. [Article]
- Takahama K, Wakuda I, Fukushima H, Isohama Y, Kai H, Miyata T: Differential effect of codeine on coughs caused by mechanical stimulation of two different sites in the airway of guinea pigs. Eur J Pharmacol. 1997 Jun 18;329(1):93-7. [Article]
- Straube C, Derry S, Jackson KC, Wiffen PJ, Bell RF, Strassels S, Straube S: Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database Syst Rev. 2014 Sep 19;(9):CD006601. doi: 10.1002/14651858.CD006601.pub4. [Article]
- Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A: Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18(37):5994-6004. doi: 10.2174/138161212803582469. [Article]
- Prommer E: Role of codeine in palliative care. J Opioid Manag. 2011 Sep-Oct;7(5):401-6. [Article]
- Lotsch J: Opioid metabolites. J Pain Symptom Manage. 2005 May;29(5 Suppl):S10-24. doi: 10.1016/j.jpainsymman.2005.01.004. [Article]
- Al-Hasani R, Bruchas MR: Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011 Dec;115(6):1363-81. doi: 10.1097/ALN.0b013e318238bba6. [Article]
- Pan HL, Wu ZZ, Zhou HY, Chen SR, Zhang HM, Li DP: Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther. 2008 Jan;117(1):141-61. doi: 10.1016/j.pharmthera.2007.09.003. Epub 2007 Sep 22. [Article]
- Codeine phosphate tablets, 30mg [Link]
- DailyMed: Codeine and promethazine syrup [Link]
- Codittusin, DailyMed [Link]
- FDA Approved Drug Products: CODEINE SULFATE tablets, for oral use CII (Jan 2024) [Link]
- FDA Approved Drug Products: Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for oral use, CIII (Jan 2024) [Link]
- EPAR, Codeine [File]
- Codeine, MedSafe NZ document [File]
Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more.
Preview package
Packagers
- Actavis Group
- Aidarex Pharmacuticals LLC
- Amarin Pharmaceuticals
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- Apotheca Inc.
- A-S Medication Solutions LLC
- Athlon Pharmaceuticals Inc.
- Barr Pharmaceuticals
- BASF Corp.
- Blansett Pharmacal Co. Inc.
- Blenheim Pharmacal
- Breckenridge Pharmaceuticals
- Bryant Ranch Prepack
- C.O. Truxton Inc.
- Cardinal Health
- Carlisle Laboratories Inc.
- Centurion Labs
- Century Pharmaceuticals Inc.
- Cerovene Inc.
- Comprehensive Consultant Services Inc.
- Corepharma LLC
- Coupler Enterprises Inc.
- D.M. Graham Laboratories Inc.
- DAVA Pharmaceuticals
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Duramed
- Eon Labs
- Glenmark Generics Ltd.
- Golden State Medical Supply Inc.
- Great Southern Laboratories
- H and H Laboratories
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Hi Tech Pharmacal Co. Inc.
- Hospira Inc.
- Innoviant Pharmacy Inc.
- Ivax Pharmaceuticals
- Janssen-Ortho Inc.
- Jerome Stevens Pharmaceuticals Inc.
- Kaiser Foundation Hospital
- Keltman Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Lannett Co. Inc.
- Lehigh Valley Technologies Inc.
- Liberty Pharmaceuticals
- Major Pharmaceuticals
- Mallinckrodt Inc.
- Mckesson Corp.
- MCR American Pharmaceuticals Inc.
- Medvantx Inc.
- Mikart Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mutual Pharmaceutical Co.
- Nexgen Pharma Inc.
- Novartis AG
- Nucare Pharmaceuticals Inc.
- Ortho-McNeil-Janssen Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Patient First Corp.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Association
- Pharmedix
- Pharmpak Inc.
- Physicians Total Care Inc.
- Poly Pharmaceuticals Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Qualitest
- Ranbaxy Laboratories
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Roxane Labs
- Sandhills Packaging Inc.
- SJ Pharmaceuticals LLC
- Southwood Pharmaceuticals
- St Mary’s Medical Park Pharmacy
- Stanley Pharmaceuticals Ltd.
- Stat Rx Usa
- Talbert Medical Management Corp.
- Teva Pharmaceutical Industries Ltd.
- TG United Inc.
- UDL Laboratories
- United Research Laboratories Inc.
- Va Cmop Dallas
- Valeant Ltd.
- Vascondor Inc.
- Veratex Corp.
- Vintage Pharmaceuticals Inc.
- Watson Pharmaceuticals
- West-Ward Pharmaceuticals
- Wockhardt Ltd.
Dosage Forms
Prices
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
StateSolid
Experimental Properties
| Property | Value | Source |
|---|
| melting point (°C) | 154-156 | MSDS |
| boiling point (°C) | 250 | http://www.chm.bris.ac.uk/webprojects2002/winder/information.htm |
| water solubility | soluble in water | http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con126132.pdf |
| logP | 1.39 | https://www.agilent.com/cs/library/applications/5990-9625EN.pdf |
| logS | -1.52 | ADMET & DMPK 1(4) (2013) 48-62; doi: 10.5599/admet.1.4.24 |
| pKa | 8.2 | http://www.inchem.org/documents/pims/pharm/codeine.htm |
Predicted ADMET Features
| Property | Value | Probability |
|---|
| Human Intestinal Absorption | + | 0.9966 |
| Blood Brain Barrier | + | 0.9979 |
| Caco-2 permeable | + | 0.8867 |
| P-glycoprotein substrate | Substrate | 0.8631 |
| P-glycoprotein inhibitor I | Inhibitor | 0.5435 |
| P-glycoprotein inhibitor II | Non-inhibitor | 0.8724 |
| Renal organic cation transporter | Inhibitor | 0.638 |
| CYP450 2C9 substrate | Non-substrate | 0.7698 |
| CYP450 2D6 substrate | Substrate | 0.9274 |
| CYP450 3A4 substrate | Substrate | 0.7796 |
| CYP450 1A2 substrate | Non-inhibitor | 0.6494 |
| CYP450 2C9 inhibitor | Non-inhibitor | 0.8866 |
| CYP450 2D6 inhibitor | Inhibitor | 0.6978 |
| CYP450 2C19 inhibitor | Non-inhibitor | 0.8256 |
| CYP450 3A4 inhibitor | Non-inhibitor | 0.8899 |
| CYP450 inhibitory promiscuity | Low CYP Inhibitory Promiscuity | 0.747 |
| Ames test | Non AMES toxic | 0.9133 |
| Carcinogenicity | Non-carcinogens | 0.9567 |
| Biodegradation | Not ready biodegradable | 0.9935 |
| Rat acute toxicity | 2.8450 LD50, mol/kg | Not applicable |
| hERG inhibition (predictor I) | Weak inhibitor | 0.8556 |
| hERG inhibition (predictor II) | Non-inhibitor | 0.8615 |
ADMET data is predicted using
admetSAR, a free tool for evaluating chemical ADMET properties. (
23092397)
Mass Spec (NIST)Not Available
Spectra
| Spectrum | Spectrum Type | Splash Key |
|---|
| Predicted GC-MS Spectrum – GC-MS | Predicted GC-MS | splash10-00lr-3090000000-38668348c3e45e16a9e7 |
| Mass Spectrum (Electron Ionization) | MS | splash10-01ot-3950000000-e80ecb11646b4da6aa92 |
| LC-MS/MS Spectrum – LC-ESI-ITFT (LTQ Orbitrap XL Thermo Scientific) 60V, Positive | LC-MS/MS | splash10-0uxr-0973000000-87d07ddd2ed24b9598d7 |
| LC-MS/MS Spectrum – LC-ESI-QTOF , positive | LC-MS/MS | splash10-0udi-0009000000-d68b67071bf467a42afa |
| LC-MS/MS Spectrum – LC-ESI-QTOF , positive | LC-MS/MS | splash10-0udi-0009000000-a298cedb776a11677cf7 |
| LC-MS/MS Spectrum – LC-ESI-QTOF , positive | LC-MS/MS | splash10-0udi-0459000000-1a92521b38ba51a7fa81 |
| LC-MS/MS Spectrum – LC-ESI-QTOF , positive | LC-MS/MS | splash10-0gc1-0940000000-68cae285315cfe9c7d0e |
| LC-MS/MS Spectrum – LC-ESI-QTOF , positive | LC-MS/MS | splash10-0uxs-0910000000-b0c288c76c616e1a54d3 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0159-0390000000-ac30542a576060b3373c |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0udi-0009000000-870de7833257cd342810 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0udi-0009000000-8ece718ed46e5e439112 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0udi-0139000000-7880499a47dbd2f41229 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0uxr-0973000000-87d07ddd2ed24b9598d7 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-015a-0920000000-4f676c9e2b42320493af |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0uxr-0910000000-e67964930533268605cd |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0udi-0009000000-99b083bf48ae39e3cec6 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0udi-0009000000-efebfbff05a4cb72fe32 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0udi-0139000000-be0f9b6eaa028b54ad6c |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0uxr-0973000000-89bc81638a52beefd890 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-015a-0920000000-7eccc8e19d8d88b18128 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0uxr-0910000000-5809a9ed32210bcfa231 |
| LC-MS/MS Spectrum – LC-ESI-ITFT , positive | LC-MS/MS | splash10-0159-0390000000-a7469c01c0a4ff4179bf |
| LC-MS/MS Spectrum – LC-ESI-QQ , positive | LC-MS/MS | splash10-0uyi-1952000000-3db61b1a0c8cde5b8c82 |
| LC-MS/MS Spectrum – LC-ESI-QQ , positive | LC-MS/MS | splash10-0lea-1940000000-b491506c23f09adaee8c |
| LC-MS/MS Spectrum – LC-ESI-QQ , positive | LC-MS/MS | splash10-0lea-1930000000-48dcc53ac80bf97d1f2d |
| Predicted MS/MS Spectrum – 10V, Positive (Annotated) | Predicted LC-MS/MS | splash10-0udi-0019000000-43c94fe9b728ab029a04 |
| Predicted MS/MS Spectrum – 20V, Positive (Annotated) | Predicted LC-MS/MS | splash10-0udi-0069000000-8aeb7e787640fef4df6c |
| Predicted MS/MS Spectrum – 10V, Negative (Annotated) | Predicted LC-MS/MS | splash10-0002-0090000000-81e646137f862ed833e3 |
| Predicted MS/MS Spectrum – 40V, Positive (Annotated) | Predicted LC-MS/MS | splash10-0006-0191000000-aa0cc448145b0a2187e1 |
| Predicted MS/MS Spectrum – 20V, Negative (Annotated) | Predicted LC-MS/MS | splash10-0002-0090000000-ed5f70501fbf3b0db16a |
| Predicted MS/MS Spectrum – 40V, Negative (Annotated) | Predicted LC-MS/MS | splash10-0fu2-0090000000-c940b27cda2c20e032c2 |
| Predicted 1H NMR Spectrum | 1D NMR | Not Applicable |
| Predicted 13C NMR Spectrum | 1D NMR | Not Applicable |
Chromatographic Properties
Collision Cross Sections (CCS)
| Adduct | CCS Value (Å2) | Source type | Source |
|---|
| [M-H]- | 174.847793 | predicted | DarkChem Lite v0.1.0 |
| [M-H]- | 175.160093 | predicted | DarkChem Lite v0.1.0 |
| [M-H]- | 174.739793 | predicted | DarkChem Lite v0.1.0 |
| [M-H]- | 174.61856 | predicted | DeepCCS 1.0 (2019) |
| [M+H]+ | 174.899893 | predicted | DarkChem Lite v0.1.0 |
| [M+H]+ | 175.225793 | predicted | DarkChem Lite v0.1.0 |
| [M+H]+ | 175.147793 | predicted | DarkChem Lite v0.1.0 |
| [M+H]+ | 177.01411 | predicted | DeepCCS 1.0 (2019) |
| [M+Na]+ | 174.999293 | predicted | DarkChem Lite v0.1.0 |
| [M+Na]+ | 175.306393 | predicted | DarkChem Lite v0.1.0 |
| [M+Na]+ | 175.051793 | predicted | DarkChem Lite v0.1.0 |
| [M+Na]+ | 184.3921 | predicted | DeepCCS 1.0 (2019) |
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
KindProtein
OrganismHumans
Pharmacological action
Yes
General FunctionReceptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)
Specific Functionbeta-endorphin receptor activity
Gene NameOPRM1
Uniprot NameMu-type opioid receptor
Molecular Weight44778.855 Da
References
- Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8. [Article]
- Raffa RB: A novel approach to the pharmacology of analgesics. Am J Med. 1996 Jul 31;101(1A):40S-46S. doi: 10.1016/s0002-9343(96)00137-4. [Article]
- Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Deprez B: From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. J Med Chem. 2001 Oct 11;44(21):3378-90. [Article]
- Liu T, Hwang L, Burley SK, Nitsche CI, Southan C, Walters WP, Gilson MK: BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data. Nucleic Acids Res. 2025 Jan 6;53(D1):D1633-D1644. doi: 10.1093/nar/gkae1075. [Article]
- Codeine FDA label [File]
- EPAR, Codeine [File]
KindProtein
OrganismHumans
Pharmacological action
Yes
Curator commentsThis target action is based on in vitro data.
General FunctionG-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions
Specific Functiondynorphin receptor activity
Gene NameOPRK1
Uniprot NameKappa-type opioid receptor
Molecular Weight42644.665 Da
References
- Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9. [Article]
- Schmidt H, Vormfelde Sv, Klinder K, Gundert-Remy U, Gleiter CH, Skopp G, Aderjan R, Fuhr U: Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63. [Article]
KindProtein
OrganismHumans
Pharmacological action
Yes
General FunctionG-protein coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine
Specific FunctionG protein-coupled enkephalin receptor activity
Gene NameOPRD1
Uniprot NameDelta-type opioid receptor
Molecular Weight40368.235 Da
References
- Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9. [Article]
- Schmidt H, Vormfelde Sv, Klinder K, Gundert-Remy U, Gleiter CH, Skopp G, Aderjan R, Fuhr U: Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63. [Article]
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
- Poulain R, Horvath D, Bonnet B, Eckhoff C, Chapelain B, Bodinier MC, Deprez B: From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. J Med Chem. 2001 Oct 11;44(21):3378-90. [Article]
- Liu T, Hwang L, Burley SK, Nitsche CI, Southan C, Walters WP, Gilson MK: BindingDB in 2024: a FAIR knowledgebase of protein-small molecule binding data. Nucleic Acids Res. 2025 Jan 6;53(D1):D1633-D1644. doi: 10.1093/nar/gkae1075. [Article]
- ChemBL resource, opioid receptors [Link]
Enzymes
KindProtein
OrganismHumans
Pharmacological action
Unknown
General FunctionA cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH–hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants
Specific Functionanandamide 11,12 epoxidase activity
Gene NameCYP2D6
Uniprot NameCytochrome P450 2D6
Molecular Weight55768.94 Da
References
- Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [Article]
- Yue QY, Sawe J: Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7. [Article]
- Flockhart Table of Drug Interactions [Link]
- Codeine FDA label [File]
KindProtein
OrganismHumans
Pharmacological action
Unknown
General FunctionA cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH–hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)
Specific Function1,8-cineole 2-exo-monooxygenase activity
Gene NameCYP3A4
Uniprot NameCytochrome P450 3A4
Molecular Weight57342.67 Da
References
- Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [Article]
- Yue QY, Sawe J: Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7. [Article]
- Codeine FDA label [File]
KindProtein
OrganismHumans
Pharmacological action
Unknown
General FunctionUDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into either the urine or bile (PubMed:10702251, PubMed:15470161, PubMed:15472229, PubMed:17442341, PubMed:18674515, PubMed:18719240, PubMed:19022937, PubMed:23288867, PubMed:23756265, PubMed:26220143, PubMed:15231852, PubMed:21422672, PubMed:38211441). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:15470161, PubMed:18674515, PubMed:23756265). Catalyzes the glucuronidation of endogenous steroid hormones such as androgens (epitestosterone, androsterone) and estrogens (estradiol, epiestradiol, estriol, catechol estrogens) (PubMed:15472229, PubMed:17442341, PubMed:18719240, PubMed:19022937, PubMed:2159463, PubMed:23288867, PubMed:26220143). Also regulates the levels of retinoic acid, a major metabolite of vitamin A involved in apoptosis, cellular growth and differentiation, and embryonic development (PubMed:10702251). Contributes to bile acid (BA) detoxification by catalyzing the glucuronidation of BA substrates, which are natural detergents for dietary lipids absorption (PubMed:23756265). Involved in the glucuronidation of arachidonic acid (AA) and AA-derived eicosanoids including 15-HETE, 20-HETE, PGE2, PGB1 and F2-isoprostanes (8-iso-PGF2alpha and 5-epi-5-F2t-IsoP) (PubMed:15231852, PubMed:38211441). Involved in the glucuronidation of the phytochemical ferulic acid at the phenolic or the carboxylic acid group (PubMed:21422672). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, caderastan and zolarsatan, drugs which can inhibit the effect of angiotensin II (PubMed:18674515). Also metabolizes mycophenolate, an immunosuppressive agent (PubMed:15470161)
Specific Functionglucuronosyltransferase activity
Gene NameUGT2B7
Uniprot NameUDP-glucuronosyltransferase 2B7
Molecular Weight60720.15 Da
References
- Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4. [Article]
- Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO: In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther. 2010 Aug;334(2):609-18. doi: 10.1124/jpet.110.167916. Epub 2010 May 18. [Article]
- Codeine FDA label [File]
KindProtein
OrganismHumans
Pharmacological action
Unknown
General FunctionUDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite’s water solubility, thereby facilitating excretion into either the urine or bile (PubMed:18719240, PubMed:23288867). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:18719240, PubMed:23288867). Catalyzes the glucuronidation of the endogenous estrogen hormones such as estradiol and estriol (PubMed:18719240, PubMed:23288867)
Specific Functionglucuronosyltransferase activity
Gene NameUGT2B4
Uniprot NameUDP-glucuronosyltransferase 2B4
Molecular Weight60512.035 Da
References
- Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO: In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther. 2010 Aug;334(2):609-18. doi: 10.1124/jpet.110.167916. Epub 2010 May 18. [Article]
- Gelston EA, Coller JK, Lopatko OV, James HM, Schmidt H, White JM, Somogyi AA: Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94. doi: 10.1111/j.1365-2125.2011.04145.x. [Article]